세계의 전임상 이미징 시장 보고서(2025년)
Preclinical Imaging Global Market Report 2025
상품코드 : 1824447
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,448,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,320,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,193,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

전임상 이미징 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.9%로 48억 1,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 개인화된 의료의 도입, 분자 이미징의 진보, 의약품 개발의 아웃소싱, 규제 당국의 지원, 만성 질환 증가 등에 기인합니다. 예측기간의 주요 동향에는 녹색 이미징 기술, 기술 진보, R&D 활동 활성화, 공동 연구 및 파트너십, 실시간 이미징 등이 포함됩니다.

향후 5년간의 성장률 6.9%라고 하는 예측은 전회 예측으로부터 0.2%의 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역마찰은 일본과 스위스에서 제조되는 고해상도 마이크로CT 스캐너와 양전자방사단층촬영-자기공명영상장치(PET-MRI 장치)의 가격을 높여 화상처리능력 저하와 학술연구소 비용 상승을 초래하여 미국 연구능력을 저해할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

예상되는 만성 질환의 급증은 전임상 이미징 시장의 성장을 크게 촉진시키는 요인이 됩니다. 만성 질환은 3개월 이상 지속되는 장기간의 건강 상태를 특징으로 하며 지속적인 의학적 관리가 필요하며 개인의 삶의 질에 큰 영향을 미칩니다. 전임상 이미징 도구는 뼈 구조와 폐 기능을 시각화하여 이러한 질병을 확인하는 데 중요한 역할을 합니다. 또한 만성 질환 연구에 기여하고 질병 진행을 시각화함으로써 전반적인 이해를 높일 수 있습니다. 예를 들어, 2022년 9월에 세계보건기구(WHO)가 발표한 2022년 하이라이트 데이터에 따르면, 세계 사망자의 74%가 비감염성 질환(NCDs) 또는 만성 질환으로 인한 것으로, 연간 4,100만 명이 사망하고 있습니다. 그 내역은 심혈관 질환에 의한 사망이 1,790만명, 암에 의한 사망이 930만명, 만성 호흡기 질환에 의한 사망이 410만명, 당뇨병에 의한 사망이 200만명입니다. 따라서 만성 질환 증가는 전임상 이미징 시장 성장의 원동력이 되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Preclinical imaging encompasses the utilization of various techniques to observe and analyze biological processes within animal models, preceding their application in human clinical trials. These imaging methods enable researchers to monitor disease progression, assess the effectiveness and safety of potential treatments, and acquire deeper insights into the underlying biological mechanisms of diseases.

Key modalities employed in preclinical imaging include optical imaging systems, preclinical nuclear imaging systems, micro-magnetic resonance imaging systems, micro-ultrasound systems, micro-computed tomography systems, preclinical photoacoustic imaging systems, and preclinical magnetic particle imaging (MPI) systems. Optical imaging systems involve technologies that leverage light to visualize and capture images of biological tissues, cells, or molecules. They are utilized during the preclinical stage for research purposes, disease diagnosis, monitoring tumor blood vessel growth, and tracking tissue blood oxygenation in animals. This encompasses a spectrum of reagents such as preclinical optical imaging reagents, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents, and preclinical CT contrast agents. Hospitals, diagnostic centers, and other entities form the primary user base for these technologies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The preclinical imaging market research report is one of a series of new reports from The Business Research Company that provides preclinical imaging market statistics, including preclinical imaging industry global market size, regional shares, competitors with a preclinical imaging market share, detailed preclinical imaging market segments, market trends and opportunities, and any further data you may need to thrive in the preclinical imaging industry. This preclinical imaging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The preclinical imaging market size has grown strongly in recent years. It will grow from $3.46 billion in 2024 to $3.69 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to government initiatives, the growing prevalence of diseases, expanding applications, increasing awareness, and emerging markets expansion.

The preclinical imaging market size is expected to see strong growth in the next few years. It will grow to $4.81 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to personalized medicine adoption, advancements in molecular imaging, drug development outsourcing, regulatory support, and rising chronic diseases. Major trends in the forecast period include green imaging technologies, technological advancements, a rise in R&D activities, collaborations and partnerships, and real-time imaging.

The forecast of 6.9% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. research capabilities by inflating prices of high-resolution micro-CT scanners and Positron Emission Tomography-Magnetic Resonance Imaging systems(PET-MRI systems) manufactured in Japan and Switzerland, resulting in reduced imaging throughput and higher academic lab costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated surge in chronic diseases is poised to be a significant driver of growth in the preclinical imaging market. Chronic diseases, characterized by prolonged health conditions lasting three months or more, necessitate ongoing medical management and can substantially impact individuals' quality of life. Preclinical imaging tools play a crucial role in identifying these diseases by visualizing bone structure and lung function. Moreover, they contribute to studying chronic diseases, enabling the visualization of disease progression and enhancing overall understanding. For instance, data from the World Health Organization (WHO) 2022 Highlights in September 2022 revealed that 74% of global deaths are caused by Noncommunicable diseases (NCDs) or chronic diseases, amounting to 41 million deaths annually. Notably, this includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Thus, the increasing prevalence of chronic diseases is a driving force behind the growth of the preclinical imaging market.

The growing demand for pharmaceutical products is set to propel the expansion of the preclinical imaging market. Pharmaceutical products, encompassing substances formulated to prevent, diagnose, or treat medical conditions, benefit significantly from preclinical imaging in the pharmaceutical industry. This imaging technology enhances decision-making by providing valuable insights into drug efficacy, safety, and mechanisms of action before progressing to clinical trials. For instance, Eurostat reported in April 2023 that exports of medicinal and pharmaceutical products increased to $307 billion (€287 billion) in 2022, reflecting a 22% rise from the previous year. Concurrently, pharmaceutical product imports increased from $107 billion (€100 billion) in 2021 to $120 billion (€112 billion) in 2022. Furthermore, the Merck Group, a Germany-based pharmaceutical company, reported in February 2023 that pharmaceutical product sales for the year 2022 reached $59.3 billion, marking a 22% increase over the full year 2021. Consequently, the heightened demand for pharmaceutical products emerges as a key driver for the growth of the preclinical imaging market.

Product innovation stands out as a prominent trend gaining traction in the preclinical imaging market, with major companies actively engaged in developing cutting-edge products to maintain their market positions. A notable example is Fujifilm VisualSonics Inc., a Canada-based biomedical company specializing in imaging systems, which introduced Vevo F2 for preclinical imaging in May 2022. Distinguished as the first preclinical ultra-high- to low-frequency (71 MHz-1 MHz) ultrasonic and photoacoustic imaging system, Vevo F2 incorporates HD image processing technology and a novel signal pathway. These features contribute to enhanced image clarity, improved frame rates, and customization options tailored to precision imaging demands. With a broad scope of anatomical targets and high-resolution imaging capabilities, Vevo F2 is well-suited for diverse research applications.

Major players in the preclinical imaging market are intensifying their focus on introducing next-generation imaging systems, positioning themselves strategically to gain a competitive advantage. Next-generation imaging systems represent advanced technologies that surpass current capabilities, integrating cutting-edge features. In a significant development, Revvity Inc., a US-based biotechnology company, launched next-generation imaging systems in September 2023, aimed at driving innovation in various preclinical research applications. The product lineup includes the next-generation IVIS Spectrum 2 and IVIS SpectrumCT 2 imaging systems, the Quantum GX3 microCT imaging solution, and a system seamlessly integrating 2D optical and full 3D imaging. These imaging systems boast enhanced image-based capabilities and are designed to streamline the imaging workflow, marking a significant stride in advancing preclinical imaging technologies.

In February 2024, Bruker Corporation, a US-based medical devices company, acquired Spectral Instruments Imaging (SII) for $37.5 million. This acquisition demonstrates Bruker's commitment to advancing scientific research and enhancing its technological capabilities in the life sciences sector. Spectral Instruments Imaging (SII) is a US-based manufacturer of preclinical optical systems for bioluminescent, fluorescent, and X-ray imaging.

Major companies operating in the preclinical imaging market include Thermo Fisher Scientific Inc., FUJIFILM Visualsonics Inc., Konica Minolta Inc., Agilent Technologies Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Miltenyi Biotech, Sofie Biosciences Inc., Promega Corporation, Ion Beam Applications S.A, Nihon Kohden, Piramal Enterprises Ltd, LI-COR Biosciences Inc., Aspect Imaging Ltd, Capintec Inc., Spectral Instruments Inc., Mediso Ltd, MR Solutions Ltd, Biospace Lab S. A., Scintica Instrumentation Inc., Trifoil Imaging, Bioscan Inc., CytoSMART Technologies B.V, Inviscan SAS, Kubtec X-ray, MILabs B.V., SCANCO Medical AG, Cristal Therapeutics.

North America was the largest region in the preclinical imaging market in 2024. The regions covered in the preclinical imaging market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the preclinical imaging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The preclinical imaging market includes of revenues earned by entities by providing preclinical imaging services such as magnetic resonance imaging, positron emission tomography, computed tomography, and optical imaging services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Preclinical Imaging Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on preclinical imaging market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for preclinical imaging ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The preclinical imaging market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Preclinical Imaging Market Characteristics

3. Preclinical Imaging Market Trends And Strategies

4. Preclinical Imaging Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Preclinical Imaging Growth Analysis And Strategic Analysis Framework

6. Preclinical Imaging Market Segmentation

7. Preclinical Imaging Market Regional And Country Analysis

8. Asia-Pacific Preclinical Imaging Market

9. China Preclinical Imaging Market

10. India Preclinical Imaging Market

11. Japan Preclinical Imaging Market

12. Australia Preclinical Imaging Market

13. Indonesia Preclinical Imaging Market

14. South Korea Preclinical Imaging Market

15. Western Europe Preclinical Imaging Market

16. UK Preclinical Imaging Market

17. Germany Preclinical Imaging Market

18. France Preclinical Imaging Market

19. Italy Preclinical Imaging Market

20. Spain Preclinical Imaging Market

21. Eastern Europe Preclinical Imaging Market

22. Russia Preclinical Imaging Market

23. North America Preclinical Imaging Market

24. USA Preclinical Imaging Market

25. Canada Preclinical Imaging Market

26. South America Preclinical Imaging Market

27. Brazil Preclinical Imaging Market

28. Middle East Preclinical Imaging Market

29. Africa Preclinical Imaging Market

30. Preclinical Imaging Market Competitive Landscape And Company Profiles

31. Preclinical Imaging Market Other Major And Innovative Companies

32. Global Preclinical Imaging Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Preclinical Imaging Market

34. Recent Developments In The Preclinical Imaging Market

35. Preclinical Imaging Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기